Active Biotech

August 07, 2013 02:46 ET

Active Biotech AB Interim Report January - June 2013

LUND, SWEDEN--(Marketwired - Aug 7, 2013) -

Events during January - June 2013:

Laquinimod

· positive results from Phase IIa study of laquinimod in active lupus nephritis

· Teva plans continued clinical development of laquinimod for the treatment of lupus nephritis

· data presented at AAN showed a slower disability progression for multiple sclerosis patients who commenced early treatment with laquinimod compared with delayed treatment

Tasquinimod

· analysis plan for Phase III trial updated; primary PFS analysis expected at the same time as first interim overall survival analysis in 2014

· Phase II follow-up study shows an impact of tasquinimod on bone metastases as measured by Bone Scan Index (BSI); results presented at ASCO

ANYARA

· improved overall survival in a subgroup of renal cell cancer patients in the Phase II/III study; results presented at ASCO

57-57 (paquinimod)

· clinical trial in systemic sclerosis concluded, evaluation under way

ISI

· patent applications filed


                                             Jan - Jun        Jan - Dec

  (MSEK)                                  2013        2012       2012
------------------------------------------------------------------------
   *    Net sales                          5.0        96.6       227.9

   *    Operating loss                  -156.5      -120.6      -163.2

   *    Net loss                        -159.2      -123.5      -175.0

   *    Earnings per share (SEK)          -2.18       -1.79       -2.54

   *    Cash and cash equivalents (MSEK) 389.1       383.7       216.7

This report is also available at www.activebiotech.com

Active Biotech AB Interim Report January - June 2013:

http://hugin.info/1002/R/1721488/573320.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1721488]

Contact Information

  • For further information, please contact:

    Tomas Leanderson
    President and CEO
    Tel: +46 (0)46-19 20 95

    Hans Kolam
    CFO
    Tel: +46 (0)46-19 20 44

    Active Biotech AB (Corp. Reg. No. 556223-9227)
    Box 724, SE- 220 07 Lund
    Tel: +46 (0)46-19 20 00
    Fax: +46 (0)46-19 11 00